WARNINGS AND PRECAUTIONS

• The use of Bosutinib is contraindicated for the, known hypersensitivity to bosutinib and liver impairment.
• Need to monitor liver enzymes at least every month in order to the initial three months and as needed. Withhold, dose reduce, or discontinue BOSULIF.
• Patients should be monitored for renal function at baseline and also during the therapy with BOSUVI.
• Females of reproductive potential should avoid becoming pregnant while being treated with Bosutinib. The medication may cause fetal harm.
• All the patients should be monitored and also should be managed by using standard of care treatment.
• If you’re willing to take an antacid or H2 blocker medicine, take it at least 2 hours before or 2 hours after Bosuvi. If you take a Proton Pump Inhibitor (PPI) medicine, talk to your healthcare provider.
• Breastfeeding should be avoided. It can harm your baby. You and your healthcare provider should decide if you will take Bosuvi or breastfeed.
• Administration of Bosulif should be avoided as it is not known if this medication is safe and effective in children who are less than 18 years of age.
• Females should use effective birth control (contraception) during and for at least 30 days after the final dose of BOSULIF. Talk to your doctor about forms of birth control that may be right for you during such circumstances.
• Patients should be advised of the possibility of developing renal problems and to immediately report frequent urination, polyuria or oliguria.